Latest News

May 14, 2019
ReViral to Present Data Showing Absence of Clinical Resistance in Volunteers Infected with RSV then Treated with Sisunatovir (RV521)

Highly encouraging resistance profile of Company’s lead drug candidate to be presented at the 32nd International Conference on Antiviral Research (ICAR)

London, UK,...

Apr 8, 2019
ReViral Announces Grant of Key US Composition of Matter Patent For Their Respiratory Syncytial Virus inhibitor programme

• Patent claims RSV fusion protein inhibitors as medicines including lead pipeline candidate, RV521; patent nominally expires in 2035 (unextended)
• The counterpart to this patent has been issued in...

Apr 5, 2019
ReViral to present at Microbiology Society Annual Conference 2019

ReViral's Chief Scientific Officer, Stuart Cockerill, will be giving an oral presentation at the Microbiology Society Annual Conference 2019 (8th-11th April) in Belfast. The presentation entitled "Design,...

Mar 20, 2019
Virologist Position (Durham Area)

ReViral are currently recruiting a Virologist to join our laboratory team based in the Durham area, UK, to support the company's antiviral drug discovery and development projects.


Feb 26, 2019
ReViral Ltd Appoints Seth Hetherington as Chief Medical Officer as it Prepares its Lead RSV Candidate to Enter Pediatric Phase IIa Clinical Trials

London, UK, 26th February 2019: ReViral Ltd., a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV), today announced the...

Nov 14, 2018
ReViral Announces Publication of Article in Journal of Medicinal Chemistry 'Perspectives'

ReViral today announced that the article “State of the Art in Respiratory Syncytial Virus Drug Discovery and Development”, written by ReViral’s Dr Stuart Cockerill, Dr James Good and Dr Neil...

Oct 8, 2018
ReViral at 11th International Respiratory Syncytial Virus Symposium

ReViral's CEO, Dr Eddy Littler, and Head of Virology, Dr Elaine Thomas, will be presenting "Low rate of resistance to the RSV fusion inhibitor RV521 in human infection" at the 11th International Respiratory...

Aug 1, 2018
ReViral announces Series B investment

ReViral announces US$55 million series B fundraising to advance RSV clinical studies

London, UK – 1st August 2018:  ReViral, an antiviral drug discovery and development company,...

Feb 5, 2018
Positive results achieved in ReViral’s Phase IIa RSV challenge study

ReViral’s RV521 fusion inhibitor produces highly significant reduction in viral load and clinical symptoms

London, UK, 5th February 2018 / ReViral, a UK-based biotech...

Archived News
Dec 5, 2018
ReViral Board member Raymond Schinazi decorated with French Legion of Honour
Oct 8, 2018
ReViral to present at RespiDART 2018
Oct 8, 2018
ReViral at 6th ISIRV AVG Conference
Sep 5, 2017
ReViral initiates Phase 2a study of RV521 for treatment of Respiratory Syncytial Virus
Apr 24, 2017
ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers
Sep 8, 2015
ReViral announces US$21 million fundraising to advance clinical development of a novel anti-viral drug
Upcoming Events
BIO 2019
Jun 3, 2019 to Jun 6, 2019
Philadelphia, PA
More Information
Jefferies Healthcare Conference
Jun 4, 2019 to Jun 7, 2019
New York
More Information
Past Events
11th International Respiratory Syncytial Virus Symposium
Oct 31, 2018 to Nov 4, 2018
Asheville, NC, USA
More Information
24th Annual BioEurope Partnering Conference
Nov 5, 2018 to Nov 7, 2018
More Information
The 6th ISIRV AVG Conference
Nov 13, 2018 to Nov 15, 2018
More Information
J.P. Morgan 37th Annual Healthcare Conference
Jan 7, 2019 to Jan 10, 2019
San Francisco
More Information
Microbiology Society Annual Conference 2019
Apr 8, 2019 to Apr 11, 2019
Belfast, UK
More Information
32nd International Conference on Antiviral Research (ICAR)
May 12, 2019 to May 15, 2019
Baltimore, USA
More Information